Bipolar androgen therapy (BAT) resulted in similar progression-free survival and reduction in prostate-specific antigen (PSA) compared with enzalutamide among men with metastatic castration-resistant prostate cancer
Назад к списку
Bipolar androgen therapy (BAT) resulted in similar progression-free survival and reduction in prostate-specific antigen (PSA) compared with enzalutamide among men with metastatic castration-resistant prostate cancer